Description: Tiziana Life Sciences PLC develops novel molecules that impact serious human diseases in oncology and immunology. It is focused on developing next-generation therapeutics and diagnostics for cancers and immune diseases.
Home Page: www.tizianalifesciences.com
TLSA Technical Analysis
55 Park Lane
London,
W1K 1NA
United Kingdom
Phone:
44 20 7495 2379
Officers
| Name | Title |
|---|---|
| Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA | Founder, Exec. Chairman & Interim CEO |
| Dr. Andrea Brancale | Scientific Founder |
| Mr. Richard Clarkson Ph.D. | Scientific Founder |
| Mr. Andrew Westwell Ph.D. | Scientific Founder |
| Ms. Keeren Shah | Chief Financial Officer |
| Dr. Matthew W. Davis M.D., RPh | Chief Medical Officer & Acting Chief Scientific Officer |
| Prof. Napoleone Ferrara M.D. | Member of Scientific Advisory Board |
| Prof. Roberto Pellicciari Ph.D. | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4989 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2000-03-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |